JE NEWS

Main Menu                 E-mail to me                 Req. of WHO

        111: Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ
        OraVax, Inc., Cambridge, Massachusetts 02139, USA.

        Molecular basis for attenuation of neurovirulence of a yellow fever
        Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
        J Virol 2001 Jan;75(2):934-42


        110: Kanesa-thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E,
        Kurane I, Tang DB, Vaughn DW, Mason PW, Shope RE.

        Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated
        recombinant Japanese encephalitis virus - poxvirus vaccines in
        vaccinia-nonimmune and vaccinia-immune humans.
        Vaccine. 2000 Oct 15;19(4-5):483-491.



 
        109: Ding Z, Shi H, Pang C.

        [Production of purified Japanese encephalitis vaccine from Vero cells
        with roller bottles].
        Chung Hua I Hsueh Tsa Chih. 1998 Apr;78(4):261-2. Chinese.


        108: Tseng CY, Hwang KP, Lin KH, Chen HY, Lu CC, Chiang CH.

        Comparison of immunogenicity of simultaneous and nonsimultaneous
        vaccination with MMR and JE vaccine among 15-month-old children.
        Taiwan Erh Ko I Hsueh Hui Tsa Chih. 1999 May-Jun;40(3):161-5.


        107: Aihara H, Takasaki T, Toyosaki-Maeda T, Suzuki R, Okuno Y,
        Kurane I.

        T-cell activation and induction of antibodies and memory T cells by
        immunization with inactivated Japanese encephalitis vaccine.
        Viral Immunol. 2000;13(2):179-86.


        106: Kurane I, Takasaki T.

        Immunogenicity and protective efficacy of the current inactivated
        Japanese encephalitis vaccine against different Japanese encephalitis
        virus strains.
        Vaccine. 2000 May 26;18 Suppl 2:33-5. Review.


        105: Markoff L.

        Points to consider in the development of a surrogate for efficacy of
        novel Japanese encephalitis virus vaccines.
        Vaccine. 2000 May 26;18 Suppl 2:26-32. Review.


        104: Tsai TF.

        New initiatives for the control of Japanese encephalitis by vaccination:
        minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.
        Vaccine. 2000 May 26;18 Suppl 2:1-25.


        103: Kumar R.

        Viral encephalitis of public health significance in India: current
        status.
        Indian J Pediatr. 1999 Jan-Feb;66(1):73-83.


        102: Broom AK, Wallace MJ, Mackenzie JS, Smith DW, Hall RA.

        Immunisation with gamma globulin to murray valley encephalitis virus and
        with an inactivated Japanese encephalitis virus vaccine as prophylaxis
        against australian encephalitis: evaluation in a mouse model.
        J Med Virol. 2000 Jun;61(2):259-65.


        101: Saito M, Sunagawa T, Makino Y, Tadano M, Hasegawa H, Kanemura
        K, Zamami Y, Killenbeck BJ, Fukunaga T.

        Three Japanese encephalitis cases in Okinawa, Japan, 1991.
        Southeast Asian J Trop Med Public Health. 1999 Jun;30(2):277-9.


        100: Reuben R, Gajanana A.

        Japanese encephalitis in India.
        Indian J Pediatr. 1997 Mar-Apr;64(2):243-51.


        99: Chang GJ, Hunt AR, Davis B.

        A single intramuscular injection of recombinant plasmid DNA induces
        protective immunity and prevents Japanese encephalitis in mice.
        J Virol. 2000 May;74(9):4244-52.


       98: Plesner A, Ronne T, Wachmann H.

        Case-control study of allergic reactions to Japanese encephalitis
        vaccine.
        Vaccine. 2000 Mar 6;18(17):1830-6.


        97: Konishi E, Yamaoka M, Kurane I, Mason PW.

        Japanese encephalitis DNA vaccine candidates expressing premembrane and
        envelope genes induce virus-specific memory B cells and long-lasting
        antibodies in swine.
        Virology. 2000 Mar 1;268(1):49-55.


        96: Zhou B, Jia L, Xu X.

        [A large-scale study on the safety and epidemiological efficacy of
        Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic
        areas].
        Chung Hua Liu Hsing Ping Hsueh Tsa Chih. 1999 Feb;20(1):38-41. Chinese.


        95: Choi JY, Woo SD, Lee HK, Hong HK, Je YH, Park JH, Song JY, An
        SH, Kang SK.

        High-level expression of canine parvovirus VP2 using Bombyx mori
        nucleopolyhedrovirus vector.
        Arch Virol. 2000;145(1):171-7.


        94: Sohn YM.

        Japanese encephalitis immunization in South Korea: past, present, and
        future.
        Emerg Infect Dis. 2000 Jan-Feb;6(1):17-24.


        93: Monath TP, Levenbook I, Soike K, Zhang ZX, Ratterree M, Draper
        K, Barrett AD, Nichols R, Weltzin R, Arroyo J, Guirakhoo F.

        Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine:
        dose-response effectiveness and extended safety testing in rhesus
        monkeys.
        J Virol. 2000 Feb;74(4):1742-51.


        92: Hsu LC, Wu YC, Lin SR, King CC, Ho MS, Lu CF, Hsu HM, Chen KT,
        Horng CB.

        [Seroepidemiology of Japanese encephalitis viral infection among 3-6
        years old children from mountainous and plains townships located in the
        northern, central, southern and eastern Taiwan].
        J Microbiol Immunol Infect. 1997 Aug;30(3):194-206. Chinese.


        91: Jou R, Kan S, Yang WJ, Huang C, Chang MK, Liau MY.

        [Study on the stability of Japanese encephalitis vaccine--development of
        freeze-dry dosage form].
        Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih. 1996
        Feb;29(1):57-64. Chinese.


        90: Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V,
        Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn
        DW.

        Safety, immunogenicity, and protective efficacy of NYVAC-JEV and
        ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys.
        Am J Trop Med Hyg. 1999 Mar;60(3):343-9.


        89: Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V,
        Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn
        DW.

        An intranasal challenge model for testing Japanese encephalitis vaccines
        in rhesus monkeys.
        Am J Trop Med Hyg. 1999 Mar;60(3):329-37.


        88: Defraites RF, Gambel JM, Hoke CH Jr, Sanchez JL, Withers BG,
        Karabatsos N, Shope RE, Tirrell S, Yoshida I, Takagi M,
        Meschievitz CK, Tsai TF.

        Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers:
        immunogenicity and safety of vaccine administered in two dosing regimens.
        Am J Trop Med Hyg. 1999 Aug;61(2):288-93.


        87: Rojanasuphot S, Shaffer N, Chotpitayasunondh T, Phumiamorn S,
        Mock P, Chearskul S, Waranawat N, Yuentrakul P, Mastro TD, Tsai
        TF.

        Response to JE vaccine among HIV-infected children, Bangkok, Thailand.
        Southeast Asian J Trop Med Public Health. 1998 Sep;29(3):443-50.


        86: Wu YC, Huang YS, Chien LJ, Lin TL, Yueh YY, Tseng WL, Chang
        KJ, Wang GR.

        The epidemiology of Japanese encephalitis on Taiwan during 1966-1997.
        Am J Trop Med Hyg. 1999 Jul;61(1):78-84.


        85: Sohn YM, Park MS, Rho HO, Chandler LJ, Shope RE, Tsai
        TF.

        Primary and booster immune responses to SA14-14-2 Japanese encephalitis
        vaccine in Korean infants.
        Vaccine. 1999 May 4;17(18):2259-64.


        84: Konishi E, Yamaoka M, Khin-Sane-Win, Kurane I, Takada K, Mason
        PW.

        The anamnestic neutralizing antibody response is critical for protection
        of mice from challenge following vaccination with a plasmid encoding the
        Japanese encephalitis virus premembrane and envelope genes.
        J Virol. 1999 Jul;73(7):5527-34.


        83: Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J,
        Barrett AD, Monath TP.

        Immunogenicity, genetic stability, and protective efficacy of a
        recombinant, chimeric yellow fever-Japanese encephalitis virus
        (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese
        encephalitis.
        Virology. 1999 May 10;257(2):363-72.


       82: Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave
       S, Myers G, Barrett AD, Shope RE, Ratterree M, Chambers TJ,
       Guirakhoo F.

        Recombinant, chimaeric live, attenuated vaccine (ChimeriVax)
        incorporating the envelope genes of Japanese encephalitis (SA14-14-2)
        virus and the capsid and nonstructural genes of yellow fever (17D) virus
        is safe, immunogenic and protective in non-human primates.
        Vaccine. 1999 Apr 9;17(15-16):1869-82.


        81: Matsunaga Y, Yabe S, Taniguchi K, Nakayama M, Kurane I.

        [Current status of Japanese encephalitis in Japan].
        Kansenshogaku Zasshi. 1999 Feb;73(2):97-103. Japanese.


        80: Plesner AM, Arlien-Soborg P, Herning M.

        Neurological complications to vaccination against Japanese encephalitis.
        Eur J Neurol. 1998 Sep;5(5):479-485.
        [Record as supplied by publisher]


        79: Chambers TJ, Nestorowicz A, Mason PW, Rice CM.

        Yellow fever/Japanese encephalitis chimeric viruses: construction and
        biological properties.
        J Virol. 1999 Apr;73(4):3095-101.


        78: Huang JH, Wey JJ, Sun YC, Chin C, Chien LJ, Wu YC.

        Antibody responses to an immunodominant nonstructural 1 synthetic
        peptide in patients with dengue fever and dengue hemorrhagic fever.
        J Med Virol. 1999 Jan;57(1):1-8.


        77: Beecham III HJ, Pock AR, May LA, Tsai TF.

        A Cluster of Severe Reactions Following Improperly Administered Takeda
        Japanese Encephalitis Vaccine.
        J Travel Med. 1997 Mar 1;4(1):8-10.
        [Record as supplied by publisher]


        76: Robinson P, Ruff T, Kass R.

        Australian Case-Control Study of Adverse Reactions to Japanese
        Encephalitis Vaccine.
        J Travel Med. 1995 Sep 1;2(3):159-164.
        [Record as supplied by publisher]


        75: Konishi E, Kurane I, Mason PW, Shope RE, Kanesa-Thasan N,
              Smucny JJ, Hoke CH Jr, Ennis FA.

        Induction of Japanese encephalitis virus-specific cytotoxic T
        lymphocytes in humans by poxvirus-based JE vaccine candidates.
        Vaccine. 1998 May;16(8):842-9.


        74: Konishi E, Yamaoka M, Khin-Sane-Win, Kurane I, Mason
              PW.

        Induction of protective immunity against Japanese encephalitis in mice
        by immunization with a plasmid encoding Japanese encephalitis virus
        premembrane and envelope genes.
        J Virol. 1998 Jun;72(6):4925-30.


        73: Chippaux A.

        [Unauthorized vaccines put on the market are useful for certain
        travelers].
        Bull Soc Pathol Exot. 1997;90(4):240-2. French.


        72: Ni H, Barrett AD.

        Attenuation of Japanese encephalitis virus by selection of its mouse
        brain membrane receptor preparation escape variants.
        Virology. 1998 Feb 1;241(1):30-6.


        71: Tsai TF, Yu YX, Jia LL, Putvatana R, Zhang R, Wang S, Halstead
              SB.

        Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis
        vaccine--a comparison of 1- and 3-month immunization schedules.
        J Infect Dis. 1998 Jan;177(1):221-3.


        70: Joshi AM, Walimbe AM, Banerjee K.

        Potency testing of inactivated tissue culture vaccine against Japanese
        encephalitis using antigen capture ELISA.
        Acta Virol. 1997 Jun;41(3):157-9.


        69: Siraprapasiri T, Sawaddiwudhipong W, Rojanasuphot S.

        Cost benefit analysis of Japanese encephalitis vaccination program in
        Thailand.
        Southeast Asian J Trop Med Public Health. 1997 Mar;28(1):143-8.
 

        68: Shyu WR, Wang YC, Chin C, Chen WJ.

        Assessment of neutralizing antibodies elicited by a vaccine (Nakayama)
        strain of Japanese encephalitis virus in Taiwan.
        Epidemiol Infect. 1997 Aug;119(1):79-83.
 

        67: Plesner AM, Ronne T.

        Allergic mucocutaneous reactions to Japanese encephalitis vaccine.
        Vaccine. 1997 Aug;15(11):1239-43.
 

        66: Takahashi M.Related Articles

        [Prevention of virus-related neurological diseases by vaccines].
        Nippon Rinsho. 1997 Apr;55(4):954-8. Review. Japanese.
 

        65: Konishi E, Win KS, Kurane I, Mason PW, Shope RE, Ennis
              FA.

        Particulate vaccine candidate for Japanese encephalitis induces
        long-lasting virus-specific memory T lymphocytes in mice.
        Vaccine. 1997 Feb;15(3):281-6.
 

        64: Sakaguchi M, Yoshida M, Kuroda W, Harayama O, Matsunaga Y,
              Inouye S.

        Systemic immediate-type reactions to gelatin included in Japanese
        encephalitis vaccines.
        Vaccine. 1997 Feb;15(2):121-2.
 

        63: Konishi E, Kurane I, Mason PW, Shope RE, Ennis FA.

        Poxvirus-based Japanese encephalitis vaccine candidates induce JE
        virus-specific CD8+ cytotoxic T lymphocytes in mice.
        Virology. 1997 Jan 20;227(2):353-60.


        62: Yeolekar LR, Banerjee K.

        Immunogenicity of immunostimulating complexes of Japanese encephalitis
        virus in experimental animals.
        Acta Virol. 1996 Nov-Dec;40(5-6):245-50.


        61: Yeolekar LR, Banerjee K.

        Preparation and characterization of immunostimulating complexes (ISCOMs)
        of Japanese encephalitis virus.
        Vaccine. 1996 Nov;14(16):1553-9.


        60: Nothdurft HD, Jelinek T, Marschang A, Maiwald H, Kapaun A,
              Loscher T.

        Adverse reactions to Japanese encephalitis vaccine in travellers.
        J Infect. 1996 Mar;32(2):119-22.


        59: Konishi E, Mason PW, Shope RE.

        Enzyme-linked immunosorbent assay using recombinant antigens for
        serodiagnosis of Japanese encephalitis.
        J Med Virol. 1996 Jan;48(1):76-9.


        58: Nimmannitya S, Hutamai S, Kalayanarooj S, Rojanasuphot
              S.

        A field study on Nakayama and Beijing strains of Japanese encephalitis
        vaccines.
        Southeast Asian J Trop Med Public Health. 1995 Dec;26(4):689-93.


        57: Gowal D, Tahlan AK.

        Evaluation of effectiveness of mouse brain inactivated Japanese
        encephalitis vaccine produced in India.
        Indian J Med Res. 1995 Dec;102:267-71.


        56: Seif SA, Morita K, Matsuo S, Hasebe F, Igarashi A.

        Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese
        encephalitis virus E-protein expressed in recombinant Escherichia coli
        system.
        Vaccine. 1995 Nov;13(16):1515-21.


        55: Cao JX, Ni H, Wills MR, Campbell GA, Sil BK, Ryman KD, Kitchen
              I, Barrett AD.

        Passage of Japanese encephalitis virus in HeLa cells results in
        attenuation of virulence in mice.
        J Gen Virol. 1995 Nov;76 ( Pt 11):2757-64.


        54: Manome Y, Wen PY, Hershowitz A, Tanaka T, Rollins BJ, Kufe DW,
              Fine HA.

        Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an
        effective tumor vaccine strategy for non-intracranial tumors.
        Cancer Immunol Immunother. 1995 Oct;41(4):227-35.


        53: Konishi E, Kurane I, Mason PW, Innis BL, Ennis FA.

        Japanese encephalitis virus-specific proliferative responses of human
        peripheral blood T lymphocytes.
        Am J Trop Med Hyg. 1995 Sep;53(3):278-83.


        52: Luo D, Ying H, Yao R, Song J, Wang Z.

        Socio-economic status and micro-environmental factors in relation to the
        risk of Japanese encephalitis: a case-control study.
        Southeast Asian J Trop Med Public Health. 1995 Jun;26(2):276-9.


        51: Lee T, Komiya T, Watanabe K, Aizawa C, Hashimoto H.

        Immune response in mice infected with the attenuated Japanese
        encephalitis vaccine strain SA14-14-2.
        Acta Virol. 1995 Jun;39(3):161-4.


        50: Lee T, Komiya T, Watanabe K, Aizawa C, Hashimoto H.

        Differences in haemagglutination activity and electrophoretic mobility
        of E protein between the parent SA14 and attenuated vaccine SA14-14-2
        strains of Japanese encephalitis virus.
        Acta Virol. 1995 Apr;39(2):109-11.


        49: Ni H, Chang GJ, Xie H, Trent DW, Barrett AD.

        Molecular basis of attenuation of neurovirulence of wild-type Japanese
        encephalitis virus strain SA14.
        J Gen Virol. 1995 Feb;76 ( Pt 2):409-13.


        48: Luo D, Yin H, Xili L, Song J, Wang Z.

        The efficacy of Japanese encephalitis vaccine in Henan, China: a
        case-control study.
        Southeast Asian J Trop Med Public Health. 1994 Dec;25(4):643-6.


        47: Ku CC, King CC, Lin CY, Hsu HC, Chen LY, Yueh YY, Chang
              GJ.
        Homologous and heterologous neutralization antibody responses after
        immunization with Japanese encephalitis vaccine among Taiwan children.
        J Med Virol. 1994 Oct;44(2):122-31.


        46: Soni GR.

        Effect of pregnancy on protection of mice immunized by Japanese
        encephalitis virus & its experimental inactivated vaccine.
        Indian J Med Res. 1994 Aug;100:57-8.



        45: Tadano M, Kanemura K, Arakaki S, Makino Y, Fukunaga T, Hokama
              T, Kyan T, Makiya H, Taira Y, Ohama N, et al.

        Epidemiological and ecological studies of Japanese encephalitis in
        Okinawa, subtropical area in Japan. II. Prevalence of Japanese
        encephalitis antibody in residents in Okinawa, Miyako and Ishigaki
        islands.
        Microbiol Immunol. 1994;38(2):123-8.


        44: Kushimoto K.

        [Analysis of immune response to Japanese encephalitis virus infection in
        mice: effect of cyclosporin A on the production of HI antibody and
        interferon].
        Fukuoka Igaku Zasshi. 1993 Dec;84(12):512-9. Japanese.


        43: Mohan Rao CV, Risbud AR, Dandawate CN, Umarani UB, Ayachit VM,
              Rodrigues FM, Pavri KM.

        Serological response to Japanese encephalitis vaccine in a group of
        school children in South Arcot district of Tamil Nadu.
        Indian J Med Res. 1993 Mar;97:53-9.


       42: [No authors listed]

        Inactivated Japanese encephalitis virus vaccine. Recommendations of the
        Advisory Committee on Immunization Practices (ACIP).
        MMWR Morb Mortal Wkly Rep. 1993 Jan 8;42(RR-1):1-15.


        41: Hase T, Dubois DR, Summers PL, Downs MB, Ussery MA.

        Comparison of replication rates and pathogenicities between the SA14
        parent and SA14-14-2 vaccine strains of Japanese encephalitis virus in
        mouse brain neurons.
        Arch Virol. 1993;130(1-2):131-43.


        40: Wills MR, Singh BK, Debnath NC, Barrett AD.

        Immunogenicity of wild-type and vaccine strains of Japanese encephalitis
        virus and the effect of haplotype restriction on murine immune  responses.
        Vaccine. 1993;11(7):761-6. 


        39: Wills MR, Sil BK, Cao JX, Yu YX, Barrett AD.

        Antigenic characterization of the live attenuated Japanese encephalitis
        vaccine virus SA14-14-2: a comparison with isolates of the virus
        covering a wide geographic area.
        Vaccine. 1992;10(12):861-72. 


        38: Igarashi A.

        Epidemiology and control of Japanese encephalitis.
        World Health Stat Q. 1992;45(2-3):299-305.


        37: Sil BK, Wills MR, Cao JX, Sharda R, Islam MA, Stagg DJ,
              Jennings AD, Gibson CA, Barrett AD.

        Immunogenicity of experimental live attenuated Japanese encephalitis
        vaccine viruses and comparison with wild-type strains using monoclonal
        and polyclonal antibodies.
        Vaccine. 1992;10(5):329-33.


        36: Gupta RK, Misra CN, Gupta VK, Saxena SN.

        An efficient method for production of purified inactivated Japanese
        encephalitis vaccine from mouse brains.
        Vaccine. 1991 Dec;9(12):865-7.


        35: Gowal D, Singh G, Bhau LN, Saxena SN.

        Thermostability of Japanese encephalitis vaccine produced in India.
        Biologicals. 1991 Jan;19(1):37-40. 



 
        34: Yasui K, Miyamoto M, Kimura-Kuroda J, Yasuda A, Matsuura Y,
              Sato T, Kojima A, Kubonoya H.

        Analysis of Japanese encephalitis (JE) virus genome and implications for
        recombinant JE vaccine.
        Southeast Asian J Trop Med Public Health. 1990 Dec;21(4):663-9.


        33: Khanina MK, Bochkova NG, Grachev VP, El'bert LB, Vorob'eva MS,
              Borsuk EA, Pogodina VV.

        [Immunogenicity and stability of a Soviet inactivated cultured vaccine
        against Japanese encephalitis].
        Vopr Virusol. 1990 Nov-Dec;35(6):478-80. Russian.


        32: Gupta RK, Misra CN, Mehta VK, Gupta VK, Bhau LN, Singh G,
              Gowal D, Saxena SN.

        Indirect haemagglutination test for the assay of antibodies against
        Japanese encephalitis viral antigen in human & animal sera.
        Indian J Med Res. 1990 Sep;91:315-20.


        31: Nitayaphan S, Grant JA, Chang GJ, Trent DW.

        Nucleotide sequence of the virulent SA-14 strain of Japanese
        encephalitis virus and its attenuated vaccine derivative, SA-14-14-2.
        Virology. 1990 Aug;177(2):541-52.30: Poland JD, Cropp CB, Craven RB, Monath
        TP.


        30: Poland JD, Cropp CB, Craven RB, Monath TP.

        Evaluation of the potency and safety of inactivated Japanese
        encephalitis vaccine in US inhabitants.
        J Infect Dis. 1990 May;161(5):878-82.


        29: Srivastava AK, Morita K, Igarashi A.Related Articles

        Immunogenicity of peptides cleaved by cyanogen bromide from Japanese
        encephalitis virus envelope glycoprotein E.
        Acta Virol. 1990 May;34(3):228-38. 


        28: Pongpairoj S, Choakouychai B, Boonrueng C, Kutirakan P,
              Ahandrik S, Leelasiri K, Phanthumachinda B.

        A test production of inactivated mouse brain JE vaccine in Thailand.
        Southeast Asian J Trop Med Public Health. 1989 Dec;20(4):647-52. No
        abstract available.
 



 
        27: Manabe S.

        Development of second generation JE vaccine with genetic engineering
        techniques.
        Southeast Asian J Trop Med Public Health. 1989 Dec;20(4):643-6. No
        abstract available.



        26: Saxena SN, Bhau LN, Singh G, Gowal D, Sood YK, Misra CN, Das
              BK.

        Immune status of volunteers one year after administration of Japanese
        encephalitis vaccine produced in India.
        Indian J Med Res. 1989 Nov;89:362-7.


       25: Fang QA, Chen BQ.

        [Effect of cytoxan on immune response of Japanese encephalitis virus
        killed and live vaccines].
        Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao. 1989 Oct;11(5):317-21.
        Chinese.


        24: Peiwei G, Zhifen D, Zhongquan W.

        Experience with production of interferon and Japanese encephalitis
        vaccine in continuous cell lines.
        Dev Biol Stand. 1989;70:223-6.



        23: Eckels KH, Yu YX, Dubois DR, Marchette NJ, Trent DW, Johnson
              AJ.

        Japanese encephalitis virus live-attenuated vaccine, Chinese strain
        SA14-14-2; adaptation to primary canine kidney cell cultures and
        preparation of a vaccine for human use.
        Vaccine. 1988 Dec;6(6):513-8.


        22: Igarashi A.

        Development of the second generation Japanese encephalitis (JE) vaccine.
        Southeast Asian J Trop Med Public Health. 1988 Sep;19(3):493-500.


        21: Xin YY, Ming ZG, Peng GY, Jian A, Min LH.

        Safety of a live-attenuated Japanese encephalitis virus vaccine
        (SA14-14-2) for children.
        Am J Trop Med Hyg. 1988 Aug;39(2):214-7.



        20: Gupta RK, Mehta VK, Gupta VK, Misra CN, Saxena SN.

        The standardization of the reverse indirect haemagglutination test for
        the assay of the viral antigen of Japanese encephalitis vaccine.
        J Biol Stand. 1987 Jul;15(3):271-9.


        19: Okuno Y, Okamoto Y, Yamada A, Baba K, Yabuuchi H.

        Effect of current Japanese encephalitis vaccine on different strains of
        Japanese encephalitis virus.
        Vaccine. 1987 Jun;5(2):128-32.



        18: Okamoto Y, Okuno Y, Yamada A, Baba K, Yabuuchi H.

        Enzyme-linked immunosorbent assay for detection of serum antibody in
        children vaccinated with Japanese encephalitis vaccine.
        Biken J. 1986 Dec;29(3-4):57-62.
 


        17: Angsubhakorn S, Moe JB, Latendresse JR, Ward GS, Ngamprochana
              M, Sahaphong S, Bhamarapravati N.

        The neurovirulence of flaviviruses in crab-eating monkeys (Macaca
        fascicularis).
        Southeast Asian J Trop Med Public Health. 1986 Dec;17(4):604-12.
 


       16: Yamada A, Imanishi J, Juang RF, Fukunaga T, Okuno Y, Tadano M,
              Fukai K, Baba K, Yabuuchi H.

        Trial of inactivated Japanese encephalitis vaccine in children with
        underlying diseases.
        Vaccine. 1986 Mar;4(1):32-4.


        15: Rodrigues FM, Mohan Rao CV, Mandke VB, Pinto BD, Pavri               K.

        Neutralizing antibody response to Japanese encephalitis inactivated
        mouse brain vaccine among laboratory personnel.
        Trans R Soc Trop Med Hyg. 1986;80(2):301-4.



        14: Cammack N, Gould EA.

        Conditions for haemolysis by flaviviruses and characterization of the
        haemolysin.
        J Gen Virol. 1985 Oct;66 ( Pt 10):2291-6.



        13: Kayser M, Klein H, Paasch I, Pilaski J, Blenk H, Heeg
              K.

        Human antibody response to immunization with 17D yellow fever and
        inactivated TBE vaccine.
        J Med Virol. 1985 Sep;17(1):35-45.



         12: Juang RF, Fukai K.

        Neutralizing antibody responses to Japanese encephalitis vaccine in
        children.
        Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih. 1983
        Sep;16(3):190-7.



        11: Juang RF, Okuno Y, Fukunaga T, Tadano M, Fukai K, Baba K,
              Tsuda N, Yamada A, Yabuuchi H.

        Neutralizing antibody responses to Japanese encephalitis vaccine in
        children.
        Biken J. 1983 Mar;26(1):25-34. 


        10: El'bert LB, Semenov BF, Karaseva PS, Pervikov IuV,
              Krutianskaia GL.

        [Inactivated vaccine against Japanese encephalitis. The characteristics
        of a purified preparation from mouse brain].
        Vopr Virusol. 1983 Mar-Apr;(2):196-200. Russian.


        9: Okuno Y, Fukunaga T, Tadano M, Fukai K.

        Serological studies on a case of laboratory dengue infection.
        Biken J. 1982 Dec;25(4):163-70.


        8: Chen BQ, Beaty BJ.

        Japanese encephalitis vaccine (2-8 strain) and parent (SA 14 strain)
        viruses in Culex tritaeniorhynchus mosquitoes.
        Am J Trop Med Hyg. 1982 Mar;31(2):403-7.



        7: Susilowati S, Okuno Y, Fukunaga T, Tadano M, Juang RF, Fukai
              K.

        Neutralization antibody responses induced by Japanese encephalitis virus
        vaccine.
        Biken J. 1981 Dec;24(4):137-45.


        6: Suzuki M, Simizu B, Yabe S, Oya A, Seto H.

        Effect of cadmium on Japanese encephalitis virus infection in mice. 1.
        Acute and single-dose exposure experiment.
        Toxicol Lett. 1981 Nov;9(3):231-5.


        5: Aizawa C, Hasegawa S, Chih-Yuan C, Yoshioka I.

        Large-scale purification of Japanese encephalitis virus from infected
        mouse brain for preparation of vaccine.
        Appl Environ Microbiol. 1980 Jan;39(1):54-7.


        4: Quina MA, Thein S, Auvanich W, Okuno Y, Igarashi A, Fukai
              K.

        Changes in dengue and Japanese encephalitis (JE) antibody after JE
        vaccination.
        Biken J. 1978 Dec;21(4):149-59.


        3: Ueba N, Kimura T, Nakajima S, Kurimura T, Kitaura T.

        Field experiments on live attenuated Japanese encephalitis virus vaccine
        for swine.
        Biken J. 1978 Sep;21(3):95-103.


        2: Das BC, Chakrabarti SK, Sarkar JK, Mukherjee KK.

        Comparative study of protection by Japanese encephalitis (JE) vaccine
        against a Japanese strain and an Indian strain of JE virus.
        Indian J Pathol Microbiol. 1976 Oct;19(4):239-43. No abstract available.


        1: Okuno T, Tseng PT, Hsu ST, Huang CT, Kuo CC.

        Japanese encephalitis surveillance in China (Province of Taiwan) during
        1968-1971. II. Age-secific incidence in connection with Japanese
        encephalitis vaccination program.
        Jpn J Med Sci Biol. 1975 Oct-Dec;28(5-6):255-67.


Total list   1-10   11-20   21-30   31-40   41-50   51-60   61-70  71-80   81-90   91-100   101-110   111-...